ReviewEULAR rheumatology open2025
The treatment landscape in axial spondyloarthritis-do we need new therapies?
Review in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite major therapeutic advances, many patients with axial spondyloarthritis (axSpA) fail to achieve remission or even low disease activity with currently available advanced therapies. This highlights an urgent need to understand why treatment responses remain suboptimal and how management can be improved. Several mechanisms contribute to persistent symptoms. Misdiagnosis and overdiagnosis remain frequent, often due to nonspecific imaging findings being misattributed to axSpA. Among correctly diagnosed patients, a substantial proportion experience pain not directly driven by inflammation. Nociplastic pain-frequently associated with fatigue, anxiety, depression, and sleep disturbances-is the predominant mechanism, while neuropathic pain is less common. These patients do not benefit from escalation of anti-inflammatory therapy but instead require tailored approaches addressing nociplastic pain, including structured exercise, cognitive-behavioural therapy, and pharmacological agents. However, robust clinical trial data in axSpA populations are lacking, and studies evaluating these interventions as add-on strategies are urgently needed. A smaller but clinically important subset of patients demonstrates true treatment-refractory (TR) axSpA, with objective inflammation persisting despite multiple biologic or targeted synthetic disease-modifying antirheumatic drugs. Novel therapeutic approaches under investigation include dual-targeted therapy with complementary mechanisms, selective depletion of pathogenic T cells, modulation of the HLA-B27 immunopeptidome through endoplasmic reticulum aminopeptidase 1/2 inhibition, and blockade of macrophage migration inhibitory factor. The primary challenge in axSpA today-besides the problem of the correct diagnosis-is to optimise the use of existing therapies for pain not related to inflammation, while simultaneously developing innovative options for TR disease. Together, these efforts will determine whether remission can become an attainable goal for all patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.